Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Befriend the Trend Trading -- Ignore unavailable to you. Want to Upgrade?

To: Dr. Stoxx who wrote (2960)	2/5/1999 7:35:00 AM
From: Dr. Stoxx	Respond to of 39683

"INSIDER INFORMATION" from ABT: A close friend of mine who is in R&D for Abbot Labs told me last night that the company is nearing completion on the development of a new kind of Rx analgesic. He couldn't say much more about it than that, but looking at ABT's chart, it has come off its highs and is looking to go back down to the 40MA. Not only would that be a great BTTT play, it might also be a superb longer-term hold once news of this new drug breaks (when that would be, I don't know). ABT: timely.com A different view: timely.com Right now, though, ABT looks shortable. I always say, "Never short ABT", in part because of my friend, and in part because it has a tremendous tradition of long-term growth. Very little can be made to the downside. But if price hits or gets anywhere near the 200MA, I'm in. TC.